Quantum Leap Healthcare Collaborative
search
Agents & Results

Agent Information

The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.
Close
Close
I-SPY Trial Manuscript
Close
Close
Close
Close
I-SPY People
Close
Close
<- Back to All Agents

pertuzumab

Trade Name:
Perjeta
Company:
Genentech
Status:
Graduated
Agent Chaperone(s):
Angela DeMichele
Treatment Protocol:
Pertuzumab is an ErbB2/EGFR/ErbB3 dimerization inhibitor. Pertuzumab was administered at 840 mg (loading dose) and a 420 mg (thereafter) intravenously once every 3 weeks (q3wk), Paclitaxel was administered at 80 mg/m2 weekly (q1w), and Trastuzumab was administered at 4 mg/kg (loading dose) and 2 mg/kg (thereafter) weekly (q1w) for a total of 12 weeks. This regimen was followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
June 3, 2013
Date Left I-SPY:
August 17, 2015
No. Participants in Arm:
99
Graduating Subtypes:
HER2+, HR-HER2+, HR+HER2+
Agent Description:

Pertuzumab is a recombinant humanized monoclonal antibody targeting the extracellular dimerization domain of Her2. This inhibits Her2 dimerization with Her1, Her3, and Her4, and downstream activation of the PI3K and MAPK pathways. Specifically, pertuzumab counters increased Her2 and Her3 dimerization signaling associated with trastuzumab resistance and is used in combination with trastuzumab and chemotherapy. Pertuzumab is approved for the first line treatment of Her2 overexpressing metastatic breast cancer and for neoadjuvant and adjuvant treatment of Her2 positive breast cancer.

Notes:
Final pCR Probabilities:
Primary Manuscript:
, 
. 
 
: 
, 
. 
abstractpdfdoi link

The I-SPY Trials

Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

 
Quick Links:
Media CenterCareersInvestigator Login
© 2019  Quantum Leap Healthcare Collaborative